Clinical Research Directory

Inclusion Criteria: Patients with histologically confirmed prostate adenocarcinoma who elect for radical radiotherapy, with at least one of the following features: * clinical stage T3a N0 M0 * Gleason score 7 (4+3) or above * PSA \> 20 No evidence of nodal or distant metastatic disease WHO performance status 0-2 Life expectancy of at least 5 years Men greater than or equal to 18 years Ability to understand and willingness to sign a written informed consent document (completed prior to registration and subsequent randomization), along with willingness to co-operate with follow-up Planned to receive 12-36 months of ADT as part of standard treatment Exclusion Criteria: T stage greater than or equal to T3b / T4 Prostate volume \> 90cc Current evidence of: * inflammatory bowel disease or other chronic bowel disorder * Autoimmune disease * Active uncontrolled bacterial, viral or fungal infection * Serious uncontrolled concomitant disease * Known coagulopathy or bleeding diasthesis * Anticoagulation medication (if unsafe to insert for seed insertion) * Bilateral hip prosthesis or fixation which would interfere with standard radiation beam configuration * Concurrent experimental or cytotoxic drugs * Allergy to gold * Severe lower urinary tract symptoms - International Prostate Symptom Score (IPSS) \> 19 * Any other contra-indication to hormonal therapy or radical radiotherapy. History of: * Previous major abdominal surgery or history of bowel adhesions * Prior pelvic radiotherapy * Active malignancy within the preceding five years (other than basal cell carcinoma) Evidence of: \- Castrate-resistance (rising PSA with castrate levels of testosterone on LHRHa and anti-androgen)